| Print
Kenvue (KVUE)
Open
$21.96
Previous close
$22.04
Trade high
$22.065
Volume
37,243,230
Year high
$25.17
Year low
$17.67
Dividend yield
3.72%
Market capitalisation
$41.18 bn
P/E ratio
39.36
ISIN
US49177J1025
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Dividends
| Previous | Latest | |
|---|---|---|
| Record date | 12/02/2025 | 14/05/2025 |
| Ex-dividend date | 12/02/2025 | 14/05/2025 |
| Payment date | 26/02/2025 | 28/05/2025 |
| Amount | $0.205 | $0.205 |
Company profile
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to theirstrong brand power.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.